Acromegalic patients under treatment with Octreotide LAR (Oct), 10, 20 or 30 mg were switched to Lanreotide Autogel 120 mg (Lan) at different dose intervals: 56, 42 and 28 days respectively. Just before the fourth Lan injection, IGF-I values were measured and the dose interval for the final three injections adjusted accordingly: if IGF-I values were between 1 and 2 standard deviations (S.D.) above the age and sex related mean value, no change in dose-interval was made; if IGF-I was above 2 S.D., the dose interval was reduced (from 56 to 42 or 42 to 28 days); if the IGF-I value was below 1 S.D., the dose interval was increased (from 28 to 42 or 42 to 56 days).
The ITT population comprised 37 patients who were treated at least once; 33 were titrated and 18, 7 and 8 patients finished the study with 28, 42 and 56 day injection intervals respectively.
Median IGF-I, GH and quality of life (QUOL) values were similar at study start and end: IGF-I 89.6 and 87.9% of upper limit of normal range; GH 1.02 and 1.64 ng/ml; QUOL 66 and 66%.
Fifty-one percent of investigators preferred the Lan Injections and 26% Oct. Patients on the longer injection intervals seemed to prefer the Lan treatment more: 41, 54 and 71% of the patients in the 28, 42 and 56 day groups expressed a preference for treatment with Lan (Oct: 35, 9 and 29% respectively).
No treatment-related serious or unexpected adverse events occurred.
Conclusions: Lanreotide Autogel 120 mg injected at intervals of 28, 42 and 56 days provided equivalent control of IGF-I, GH and QUOL when compared to treatment with 30, 20 and 10 mg Octreotide LAR respectively. For patients requiring lower doses, a longer injection interval leads to a higher preference for the treatment.